The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare; Genomics testing Cooperative; Outcomes Matter Innovations (OMI)
Consulting or Advisory Role - Incyte
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Wei-Sen Lam
No Relationships to Disclose
 
Adam Schoenfeld
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; cTRL; Foresight Diagnostics; GlaxoSmithKline; Immunocore; Iovance Biotherapeutics; Obsidian Therapeutics; Oxford BioTherapeutics; Prelude Therapeutics; Regeneron; Roche; Synthekine
Research Funding - AffiniT therapeutics (Inst); Amgen (Inst); AstraZeneca; BioNTech SE; Bristol-Myers Squibb (Inst); Clasp Therapeutics (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Iovance Biotherapeutics (Inst); Legend Biotech (Inst); Lilly; Merck (Inst); PACT Pharma (Inst); Roche/Genentech; Synthekine (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Legend Biotech; Obsidian Therapeutics; Regeneron
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
 
Matthew Gubens
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Cardinal Health; Catalyst Pharmaceuticals; Foresight Diagnostics; Genentech/Roche; Johnson & Johnson/Janssen; Natera; Nuvalent, Inc.; Oncohost; Regeneron; Samsung Bioepis
Research Funding - Amgen (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Trizell (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genmab; Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Daniel Tan
Leadership - HUTCHMED (Inst)
Stock and Other Ownership Interests - PRISM.AI
Honoraria - Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeOne (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); PRISM.AI; Regeneron (Inst); Roche (Inst); Zymeworks
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Brilliant Pharmaceuticals; Pfizer; Roche
 
Enriqueta Felip
Honoraria - Amgen; Daiichi Sankyo Europe GmbH; Gilead Sciences; Janssen / Johnson & Johnson; Lilly; MSD; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Genentech/Roche; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Pfizer; PharmaMar; Pierre Fabre; Regeneron; Seagen; Tubulis GmbH
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Joanne Chiu
No Relationships to Disclose
 
Jong-Seok Lee
No Relationships to Disclose
 
James Chih Hsin Yang
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Janssen Oncology; Merck KGaA; MSD Oncology; Takeda
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; ArriVent Biopharma; AstraZeneca; Bayer; Bicycle Therapeutics; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; GlaxoSmithKline; Hexagon; I-Mab; IO Biotech; ITeos Therapeutics; LianBio; Merck; Novartis; Nuvalent, Inc.; Oxford BioTherapeutics; Pfizer; Regeneron; Samsung Bioepis; Sanofi; SERVIER; Strata Oncology; Synthekine; Transcode; Verastem
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Giovanna Finocchiaro
Travel, Accommodations, Expenses - Merck
 
Miaojun Han
Employment - AstraZeneca (I); Merck
 
Julie Kobie
Employment - Merck
Stock and Other Ownership Interests - Merck
 
John Palcza
Employment - Merck
Stock and Other Ownership Interests - Merck
 
E.J. Dettman
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Patent applications
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; BioAtla; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma; Therapaint
Consulting or Advisory Role - Abbvie; Actym Therapeutics; BioAtla; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; ImmunoGenesis; Innovent Biologics; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Jianda Yuan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Bin Zhao
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Roy Herbst
Leadership - American Association for Cancer Research; Friends of Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; Amgen; ArriVent Biopharma; AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalym; Checkpoint Therapeutics; Cybrexa Therapeutics; Genentech/Roche; Gilead/Forty Seven; I-Mab; Janssen; Junshi Pharmaceuticals; Lilly; Mediflix; Merck; NEUVOGEN; NextCure; Normunity; Novartis; Pfizer; Regeneron; Roche; Sanofi
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG